Canadian New Drug Submission for SCENESSE in EPP filed
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Clinuvel Pharmaceuticals Limited has filed a New Drug Submission to Health Canada for SCENESSE® to treat erythropoietic protoporphyria (EPP), aiming to be the first approved treatment for this condition in Canada. The submission includes data that supported previous approvals from other regulatory bodies and highlights the ongoing Patient Special Access Program for Canadian patients. The company has trained multiple specialty centers in Canada to facilitate treatment access pending regulatory approval.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Clinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL delivers increases in annual revenue, profit
- Appendix 4E and Annual Report to Shareholders 2024
- Vitiligo and Operational Update
- Afamelanotide Assists DNA Repair Response Following UVR
- CLINUVEL extends Managing Director Employment Agreement
Later from Clinuvel Pharmaceuticals
- Managing Director Presentation
- CLINUVEL prioritises three strategic programs
- SCENESSE dosage expansion under review by EMA
- Chair's letter to Shareholders
- Health Canada validates SCENESSE New Drug Submission
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals